KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Operating Leases (2018 - 2025)

Teva Pharmaceutical Industries' Operating Leases history spans 8 years, with the latest figure at $288.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases fell 2.7% year-over-year to $288.0 million, compared with a TTM value of $288.0 million through Dec 2025, down 2.7%, and an annual FY2025 reading of $288.0 million, down 2.7% over the prior year.
  • Operating Leases for Q4 2025 was $288.0 million at Teva Pharmaceutical Industries, up from $283.0 million in the prior quarter.
  • The five-year high for Operating Leases was $444.0 million in Q2 2021, with the low at $281.0 million in Q2 2024.
  • Average Operating Leases over 5 years is $342.0 million, with a median of $331.0 million recorded in 2023.
  • Year-over-year, Operating Leases surged 543.94% in 2021 and then decreased 16.86% in 2024.
  • Tracing TEVA's Operating Leases over 5 years: stood at $416.0 million in 2021, then fell by 16.11% to $349.0 million in 2022, then dropped by 8.31% to $320.0 million in 2023, then dropped by 7.5% to $296.0 million in 2024, then fell by 2.7% to $288.0 million in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Operating Leases are $288.0 million (Q4 2025), $283.0 million (Q3 2025), and $296.0 million (Q2 2025).